GET DAILY SIGNALSEntera Bio (ENTX) Advances +13.8% as Leadership Additions Support Phase 3 Plans
Key Takeaways
- ENTX shares rose roughly 13.8% over the last 30 days, climbing from a September 28 close of $2.69 to $3.06 as of the October 27 close.
- The gain drew support from board-strengthening appointments and ongoing updates around the lead osteoporosis program, EB613.
- Entera’s $275 million oversubscribed private placement from late July has extended its cash runway into 2030 and stands as the main driver behind the higher valuation.
- The stock stayed volatile, trading between a low near $2.45 and a high above $3.20 during the month as investors balanced dilution risk with Phase 3 funding needs.
- Entera remains a clinical-stage company with no meaningful revenue; its valuation rests mainly on clinical milestones, financing activity, and sentiment around its oral peptide platform.
Entera Bio (ENTX) Company Background and Focus
Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel, that develops orally delivered peptide and protein therapies intended to replace injectable options. Its proprietary N-Tab® platform aims to support once-daily oral tablet delivery of large-molecule drugs for conditions where convenience and compliance have long favored injections.
The most advanced candidate, EB613 (oral PTH(1-34)), targets osteoporosis as a potential first oral bone-building tablet. A Phase 2 study achieved its primary and secondary endpoints, and the company is now preparing a Phase 3 registrational program. The pipeline also features EB612 for hypoparathyroidism, EB618 as a GLP-1/glucagon dual agonist for obesity and metabolic disorders, and an oral GLP-2 candidate for short bowel syndrome developed with OPKO Health. As a pre-revenue biotech, Entera draws attention mainly for clinical progress and its capacity to fund later-stage work.
ENTX Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, ENTX advanced about 13.8%, moving from a September 28 close of $2.69 to $3.06 by the October 27 close. The move was not steady: shares dipped to a low near $2.45 early in October before recovering through the latter part of the month and finishing near the upper end of the recent range.
The quarterly view shows a sharper shift. Entering late July the stock traded near $2.05. The $275 million private placement announced on July 27 lifted shares sharply, and the price has since moved in a broad band between roughly $2.45 and $3.47. From late-July levels around $2, the stock has gained approximately 49% for the quarter even after easing from its late-August peak near $3.47. This re-rating stems largely from the financing rather than fresh clinical data.
Factors Behind the Recent 30-Day Move in ENTX
The 13.8% gain over the past month stems mainly from governance and leadership steps that bolster confidence in the Phase 3 strategy. On October 6 the company added Laura Hamill, a former Gilead Sciences and Amgen executive with more than 35 years of commercial experience, to its board. On October 27 Entera named Dr. Juan Camilo Arjona Ferreira, Head of Research & Development and Chief Medical Officer at Organon & Co., as a director effective December 1; his late-stage and regulatory background in women’s health aligns directly with EB613 and EB612.
Earlier in the month, on October 8, Entera shared more details on the planned Phase 3 registrational trial design for EB613. These updates, together with the stabilized financing position, helped ease dilution concerns that had weighed on the stock early in October and supported the recovery into late October. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Drivers of ENTX Performance Across the Quarter
The quarter’s key event was Entera’s $275 million oversubscribed private placement announced July 27 and priced at $2.04 per share. Led by existing investor BVF Partners with participation from Longitude Capital, Vivo Capital, TCGX, RA Capital Management, Perceptive Advisors, and other healthcare-focused funds, the financing is expected to support EB613’s Phase 3 program through an anticipated New Drug Application submission and extend the runway into 2030.
The announcement produced a sharp single-day repricing, with shares moving from around $2.05 to an intraday high above $4 before settling. In the following weeks investors weighed the funding’s strategic value against notable share dilution, resulting in the elevated yet volatile trading range observed since. The quarter’s story centers on a de-risked balance sheet and broader institutional support, offset by the execution risk typical of a pre-revenue, Phase 3-stage biotech.
Key Items to Monitor for ENTX Going Forward
Looking ahead, the primary catalyst remains execution of EB613’s Phase 3 registrational program, including trial start, enrollment progress, and any interim readouts. Investors should also track advancement of EB612 into Phase 1 under the OPKO Health collaboration and early updates on the metabolic and GLP-2 programs.
Corporate matters matter as well. The October board appointments take effect in December, and a special shareholder meeting scheduled for late November will address equity-plan amendments and executive retention awards tied to the July financing. Macroeconomic and sector conditions, including biotech financing appetite and interest-rate expectations, could shape sentiment. As a pre-revenue company with negative earnings, ENTX stays sensitive to financing news, dilution, and clinical outcomes.
Using AI Tools in My Research Process
In my own work I sometimes review Tickeron’s AI Trading Bots to see how automated strategies have performed on tickers like ENTX. The platform offers a range of algorithmic approaches that can complement fundamental analysis, and checking recent results helps me consider different angles on volatility and momentum without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ENTX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 06, 2026
ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 46 cases where ENTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENTX's RSI Indicator exited the oversold zone, 28 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ENTX as a result. In 81 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for ENTX just turned positive on October 16, 2026. Looking at past instances where ENTX's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 43 cases where ENTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
ENTX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ENTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ENTX's P/B Ratio (72.917) is slightly higher than the industry average of (3.037). P/E Ratio (-8.743) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (1428.571) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of flu medicines
Industry Biotechnology
Advertisement